Financial Analysis: Lunai Bioworks (NASDAQ:RENB) versus Climb Bio (NASDAQ:CLYM)

Lunai Bioworks (NASDAQ:RENB) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Lunai Bioworks and Climb Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-60.38%	-47.04%
Climb Bio	N/A	-23.10%	-22.47%

Earnings and Valuation

This table compares Lunai Bioworks and Climb Bio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$88.43 million	($0.77)	-2.00
Climb Bio	N/A	N/A	-$73.90 million	($0.70)	-2.81

Climb Bio is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Lunai Bioworks and Climb Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	0	0	0	0	0.00
Climb Bio	0	0	4	2	3.33

Climb Bio has a consensus target price of $9.25, suggesting a potential upside of 369.54%. Given Climb Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Lunai Bioworks.

Insider & Institutional Ownership

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by company insiders. Comparatively, 0.8% of Climb Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Lunai Bioworks has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500.

Summary

Climb Bio beats Lunai Bioworks on 9 of the 12 factors compared between the two stocks.

About Lunai Bioworks

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

About Climb Bio

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.